| Apr 4 2025 |
Mexico Bans the Cultivation of Genetically Modified Corn, Opening Door for Other Restrictions in the Future |
Beveridge & Diamond PC |
| Apr 4 2025 |
Court Rejects Challenge to FDA Approval of Ammonia-Reducing Animal Drug |
Keller and Heckman LLP |
| Apr 4 2025 |
Texas Senate Approves Two Bills Aimed at Artificial Food Additives |
Keller and Heckman LLP |
| Apr 4 2025 |
Summary Judgment Granted in Heavy Metals in Chocolate Class Action |
Keller and Heckman LLP |
| Apr 3 2025 |
Hatch-Waxman Litigation Expenses Are Deductible Under Internal Revenue Code § 162(a) |
McDermott Will & Emery |
| Apr 3 2025 |
Court Sides with RICO Complainant Who Received Tainted Medical Marijuana and with FDA on Regulating E-Cigarettes - SCOTUS Today |
Epstein Becker & Green, P.C. |
| Apr 3 2025 |
Supreme Court Rules Lost Wages May Be Recoverable Under RICO For False Advertising After Drug Test Dismissal |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Apr 2 2025 |
USDA Will Fund 543 Projects in 29 States Through Higher Blends Infrastructure Incentive Program |
Bergeson & Campbell, P.C. |
| Apr 2 2025 |
GLP-1 Receptor Agonists: Drug Litigation Overview and Trends |
Foley & Lardner LLP |
| Apr 2 2025 |
March 2025 PFAS Legislative Developments |
CMBG3 Law |
| Apr 2 2025 |
Texas Court Vacates FDA’s Laboratory Developed Test (LDT) Final Rule |
Foley & Lardner LLP |
| Apr 1 2025 |
In Landmark Ruling, Eastern District of Texas Strikes Down FDA’s Final Rule Regulating Laboratory Developed Tests |
Polsinelli PC |
| Apr 1 2025 |
New Mexico Bills Would Expand Protections for Medical Marijuana and Allow Use of Medical Psilocybin |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Apr 1 2025 |
EC Begins Public Consultation on Upcoming EU Bioeconomy Strategy |
Bergeson & Campbell, P.C. |
| Apr 1 2025 |
Updates on SB 54: CalRecycle to Take a Second Stab at Implementing Regulations |
K&L Gates LLP |
| Apr 1 2025 |
A Final Rule Bites the Dust: Federal Court Rules FDA Lacks Authority to Regulate LDTs |
Epstein Becker & Green, P.C. |
| Apr 1 2025 |
FDA Can’t Stop, Won’t Stop – Navigating the New Administration [Podcast] |
Keller and Heckman LLP |
| Apr 1 2025 |
We Never Know How High We Are Until We Are Called to Rise: Protecting Alabama’s Medical Cannabis Program |
Bradley Arant Boult Cummings LLP |
| Apr 1 2025 |
FDA Announces “Operation Stork Speed” |
Keller and Heckman LLP |
| Apr 1 2025 |
FDA’s New Transparency Tool Addresses Chemical Contaminants |
Sheppard, Mullin, Richter & Hampton LLP |
| Mar 31 2025 |
APHIS Evaluates Petitions Reviewed under 2012 Process, Will Use Process Consistent with USDA Biotechnology Regulations Going Forward |
Bergeson & Campbell, P.C. |
| Mar 31 2025 |
New Guidelines Establishing the Requirements and Procedures That Must Be Observed to Obtain Permission to Advertise Prepackaged Food and Non-Alcoholic Beverages |
OLIVARES |
| Mar 28 2025 |
HHS Job Cuts: FDA, CDC, NIH and CMS Impacted Amidst Significant Restructurings |
Polsinelli PC |
| Mar 28 2025 |
Nebraska Considers Sales Tax on Candy and Soft Drinks |
Keller and Heckman LLP |
| Mar 28 2025 |
FDA Announces a “Chemical Contaminants Transparency Tool” to Evaluate Potential Health Risks of Contaminants in Human Foods. |
Keller and Heckman LLP |
| Mar 28 2025 |
Illinois Moving Forward with BVO Ban |
Keller and Heckman LLP |
| Mar 27 2025 |
Behavioral Health Law Ledger | March 2025 |
Greenberg Traurig, LLP |
| Mar 27 2025 |
EPA Extends 2024 RFS Compliance Reporting Deadline |
Bergeson & Campbell, P.C. |
| Mar 27 2025 |
CLP Changes And What They Mean For Commercial Operations — A Conversation with Karin Baron and Lioba Oerter [Podcast] |
Bergeson & Campbell, P.C. |
| Mar 27 2025 |
China Releases New Rules Regarding the Use of Facial Recognition Technology |
Hunton Andrews Kurth |
| Mar 27 2025 |
What’s the (Re)issue? Patent Term Extensions for Reissue Patents |
McDermott Will & Emery |
| Mar 27 2025 |
China Releases Draft Implementation Measures for the Protection of Drug Trial Data Including Data Exclusivity for Foreign-Originated Drugs |
Schwegman, Lundberg & Woessner, P.A. |
| Mar 26 2025 |
Ghost Guns and the Bankruptcy Code: Neither Provides Ammunition for Dismissing Actions - SCOTUS Today |
Epstein Becker & Green, P.C. |
| Mar 26 2025 |
This Week in 340B: March 18 – 24, 2025 |
McDermott Will & Emery |
| Mar 25 2025 |
DEA Buprenorphine Rule Delayed to December 31, 2025 |
Foley & Lardner LLP |
